About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cue Biopharma, Inc. - Common Stock (NQ:CUE)

14.88 +1.88 (+14.50%)
Streaming Delayed Price Updated: 11:54 AM EDT, Apr 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cue Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q2 2024 ↗
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Forecasting The Future: 4 Analyst Projections For Cue Biopharma ↗
 
Via Benzinga
Cue Biopharma Inc. (NASDAQ: CUE) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket ↗
Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended. 
Via InvestorPlace
News headline image
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024 ↗
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023 ↗
CUE stock results show that Cue Biopharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... 
Via Benzinga
News headline image
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023 ↗
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023. 
Via InvestorPlace
News headline image
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.